COTI-2 is a small molecule drug discovered by Critical Outcome Technologies Inc. that shows promise for treating many cancers. It is effective against cancers with a p53 gene mutation and has received Orphan Drug Designation from the FDA for ovarian cancer. Experiments by MD Anderson Cancer Center independently confirmed COTI-2's novel mechanism of action and identified an effective lower dosage. Critical Outcome Technologies plans to file for FDA approval and begin a Phase 1 clinical trial at MD Anderson in early 2015 to further test the safety and efficacy of COTI-2.